OR WAIT null SECS
Transferring Energy to Hot Melt Extrusion
A greater understanding of molecular and cellular biology and technological advancements are revolutionizing the field of biologics.
The use of appropriate taste-masking and appearance technologies can facilitate patient compliance.
A comparison between polysorbates and HPβCD determines the better stabilizer for biologics formulation.
This study reviews changes in in-country testing (registration testing, import testing) requirements and analyzes current trends.
Guidance documents and interaction with FDA can help manufacturers stay in GMP compliance, says Siegfried Schmitt, VP Technical, at Parexel.
A Closer Look at mRNA in Oncology and Vaccines
May 13, 2024
Adam Covitt, President of Federal Equipment Company, discusses how the company enables CDMO successes with its Techceuticals and PharmParts business brands.
Peter DeYoung, CEO, Piramal Pharma Solutions, talks about recent company achievements and key offerings, as well as current industry trends.
May 11, 2024
The separation of deamidated capsids from non-deamidated capsids can be achieved using HIC, according to studies done by a team at Oxford Biomedica.
Phillip Gregory, PhD, senior vice-president and head of Regeneron Cell Medicines, Regeneron, discussed how engineering receptor architecture can be a tool to improve CAR-T cell sensitivity to tumor antigens.
Regeneron's Sven Moller-Tank, PhD, director of Viral Delivery Technologies, Regeneron Genetic Medicines, discusses the company's work in using bispecific antibodies for redirecting AAV target specificity.
May 10, 2024
At CPHI NA, Rachel Harris, AstraZeneca, spoke on her work at BioPhorum to enable industry consensus and action for sustainability with drug delivery devices.
May 09, 2024
Tara Dougal, content director, Pharma, Informa Markets, discusses successes and insights from this year’s CPHI North America and the agenda for the upcoming CPHI Milan.
Purna Thakker, founder and CEO of ADPT Solution, discusses common issues that companies face with FDA regulations at CPHI North America.
The company’s presentation at ASGCT includes preliminary data results for a child who received the gene therapy.